Cushing’s Community Button

Posted on May 22, 2015 by MaryO
The Community button is at the lower left.

The Community button is at the lower left.

Join in and help answer questions!

Several of the Cushing’s Help pages have a new “Community Button” near the bottom left. Click on any of those to chat away or ask questions.

Sample of the Community window

Sample of the Community window

Click on the little square symbol next to the X to undock the chat and keep it with you on other pages.

If you’re on a  a mobile device? Look at the bottom right, below the “Send” button and click on “Continue from mobile” to get your member code.

Filed under: Cushing's, FAQ | 2 Comments »

Enzyme that triggers muscle wasting could be key to REVERSING signs of ageing | Daily Mail Online

Posted on May 21, 2015 by MaryO

Drawing on expertise from both the University of Birmingham and Queen Elizabeth Hospitals Birmingham, they applied their knowledge of Cushing’s syndrome to the new problem (sarcopenia).

Cushing’s is hormonal disorder caused by high levels of cortisol. Patients suffer from the syndrome see marked changes in their body composition.

The effects can be devastating for patients who can develop features such as muscle wasting and weakness, weight gain, thinning of the bones, diabetes, high blood pressure and heart disease.

Dr Hassan-Smith said: ‘Looking at this particular enzyme seemed like an intriguing way forward.

‘We knew how it works in relation to Cushing’s Syndrome, which is characterised by similar symptoms, and thought it would be worthwhile applying what we knew to the ageing population.’

Currently there are no treatments for sarcopenia, the team explained.

But pharmaceutical companies are developing and testing ways to block or switch off the enzyme, with a focus on treatments for conditions including diabetes.

The team is excited about taking the results of their study forward into future research, with one eye on adapting the inhibitors already in development to combat muscle ageing.

Dr Hassan Smith added: ‘The next stage is a “proof of concept” study to look at the effects of these inhibitive pharmaceuticals on muscle function, before opening it up into a clinical trial.

‘It’s an as yet unexplored area that could yield beneficial results for a problem that is becoming more prevalent as our lifespans increase.’

The study was published in the journal of Clinical Endocrinology and Metabolism.

 

via Enzyme that triggers muscle wasting could be key to REVERSING signs of ageing | Daily Mail Online.

Filed under: Cushing's, General Health, Rare Diseases | Tagged: , , , , , , , , , , | 2 Comments »

Macroadenoma biochemical behavior in pediatric patients with Cushing’s disease differs from adult cases

Posted on May 15, 2015 by MaryO

Cushing’s disease in children is associated with similar biochemical measures whether the disease is due to macroadenomas or microadenomas, according to a presentation at the AACE 24th Annual Scientific & Clinical Congress.

This contrasts with the disease behavior in adults, in whom macrodenomas demonstrate less glucocorticoid suppression and adrenocorticotropic hormone (ACTH) response to laboratory tests than do microadenomas, according to researchers.

“Children with pituitary macroadenomas are more likely to have the classical response to Cushing’s disease functional testing as microadenomas,”Ricardo Correa, MD, a clinical and research endocrinology fellow at National Institutes of Health, told Endocrine Today.

Correa and colleagues conducted a retrospective review of patients with Cushing’s disease who were younger than 18 years when they were admitted to the NIH between 1997 and 2014. All Cushing’s diagnoses were confirmed by pathology.

Pituitary macroadenoma was identified in 13 patients (69% female) and microadenoma in 74 (58% female). The groups had similar mean age (14 years) and BMI (31.8 kg/m2 and 30.2 kg/m2 for macroadenoma and microadenoma, respectively). The macroadenoma group had a median (25% to 75%) 24-hour urine free cortisol of  263.60 mcg/24 hr (range 170.7-528) compared with 371.6 mcg/ 24 hr (range 244.2-625.3) in the microadenoma group (P = 0.47). Median 24-hr urinary 17-hydroxysteroid excretion in the macroadenoma group was 12.6 mg/24 hr (range 8.9-42.5) and 31.6 mg/24 hr (range 4.3-39.9) in the microadenoma group.

Mean morning serum cortisol was 38.9 ± 40.4 mcg/dL compared with  20.2 ± 15.8 mcg/dL in the macroademona and microadenoma groups, respectively (P = 0.16). Mean morning basal plasma ACTH was 106.3 ± 112.3 pg/mL compared with 49.9±44.3 pg/mL for the macroadenoma and microadenoma groups, respectively (P = 0.11), while ACTH responses to the ovine corticotropin-releasing hormone test revealed no statistically significant differences. Using the high dose dexamethasone suppression test, 58% (7/12) suppressed more than 69% in the macroadenoma group compared to 69% (44/64) in the microadenoma group (P = .51).

“Studies in adult patients have demonstrated that macroadenomas have less glucocorticoid suppressibility after the high-dose dexamethasone suppression test and attenuated ACTH response to CRH compared to pituitary microadenomas,” according to Correa. “However, the present study shows that this is not true in children; although patients with macroadenomas had a tendency for higher baseline serum ACTH and cortisol levels, their responses to dynamic testing were similar to those with microadenomas.”

Reference:

Correa R, et al. Abstract #803. Presented at: AACE 24th Annual Scientific & Clinical Congress; May 13-17, 2015; Nashville, Tenn.

Disclosure: The researchers report no relevant financial disclosures.

From http://www.healio.com/endocrinology/adrenal/news/online/%7Bb4fbf36f-ac88-4eff-9278-90f0a8d1aec2%7D/macroadenoma-biochemical-behavior-in-pediatric-patients-with-cushings-disease-differs-from-adult-cases?sc_trk=internalsearch

Filed under: Cushing's, pituitary | Tagged: , , , , , , , , , , | Leave a comment »

Cushing’s Syndrome | Seeking Alpha

Posted on May 14, 2015 by MaryO

Looking at the dizzying volatility in the government bond space and in continuation of our recent theme dealing with “alkaloids,” we remembered Cushing’s syndrome when choosing our title analogy, also known as “hypercortisolism” which is a collection of signs and symptoms due to prolonged exposure to cortisol (or QEs). Cushing’s syndrome is generally associated with rapid weight gain (bond prices), moodiness, irritability or depression to name a few.

The most common cause of Cushing’s syndrome is “exogenous” administration of glucortocoides prescribed by a health practitioner to treat other diseases such as asthma and rheumatoid arthritis. In our “market case,” one could argue that the most common cause of the sudden rise in government bond yields could be linked to the exogenous administration of “QEs” prescribed by central bankers in order to treat weak aggregate demand (AD). Strictly, Cushing’s syndrome refers to excess cortisol of any etiology (as syndrome means a group of symptoms).

 

Government bonds and Cushing’s Syndrome analogy from Cushing’s Syndrome | Seeking Alpha.

Filed under: Cushing's | Tagged: , , , | Leave a comment »

RARE Webinar: Leveraging a Rare Disease Center of Excellence

Posted on May 13, 2015 by MaryO

Screenshot 2015-05-13 19.36.00

 

 

 

As many patient advocates continue on their journey to become empowered activists, some may learn and want to consider starting a rare disease center of excellence.

This webinar covers how this can be done, what the obstacles and challenges are, and whether there are other options viewers should consider (like utilizing other centers that already exist).

If you cannot attend this, please register anyway, so we can send you details on the slides and archived event afterwards.

If you have any questions or technically issues during the event, please reach out to Katiem@globalgenes.org.

Filed under: Meetings and Conferences, Rare Diseases | Tagged: , , , | 1 Comment »

« Previous Page — Next Page »